Regeneron’s Dupixent recorded €4.25 billion in fourth-quarter sales, marking a 22.8% year-over-year gain and a 2.2% increase from the prior quarter.

The sales surge reflects expanded use across additional indications and increased patient uptake in key European and North American markets.

Dupixent’s performance further cements Regeneron and Sanofi as leaders in the immune-mediated inflammatory diseases market, accounting for a significant share of global therapy revenues.